Formation Biologics formationbiologics.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Formation Biologics is a clinical stage biopharmaceutical company that engineers protein based therapeutics for treatment of cancer and orphan diseases. The company's lead program is AVID100, an antibody-drug conjugate (ADC), intended for the treatment of EGFR-expressing malignancies. The company's second development stage program is AVID200, an isoform-selective TGF-beta inhibitor that is undergoing IND-enabling studies for use in orphan diseases and in immune oncology.

Formation Biologics is a clinical stage biopharmaceutical company that engineers protein based therapeutics for treatment of cancer and orphan diseases. The company's lead program is AVID100, an antibody-drug conjugate (ADC), intended for the treatme...Show all

Company (Alive / Active)

Phone:

Fax:

200 E 6th STreet
Suite 201
Austin, 78701
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Formation Biologics $0M May 15, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Formation Biologics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Egfr antibody-based combination therapy Oct 30, 2015 Application
Egfr antibody conjugates Jul 04, 2014 Application